CAP®-Technology for Protein Production

CEVEC has developed a new and proprietary expression platform for biopharmaceuticals based on human amniocytes. The versatile CAP® and CAP-T®  cells exhibit exceptional yields for antibodies and complex proteins and are also an excellent tool for vaccine and virus production. A unique advantage of the transiently protein producing CAP-T® cells and the stably producing CAP® cells are identical and highest product qualities provided by an isogenic cellular background.

Therefore, the costly and time-consuming classical switch of transient and stable cell expression like e.g. the 293/CHO switch in upstream cell line development can be avoided

One platform for all your needs, transient to permanent protein expression: A continuum for rapid and versatile product development. From your initial research ideas all the way to scale up and process optimization.

CAP® cell line for stable protein expression

  • Stable and very high yield expression of human proteins, including antibodies, complex proteins and vaccines.
  • Authentic human-like post-translational modifications
  • High density growth in suspension under serum-free, chemically defined conditions
  • Immortalized by a function not oncogenic in human
  • Ethically accepted source of origin
  • Allows fast and easy cell line development
  • Validated stable growth in different types of bioreactos
  • Certified Master Cell Bank (MCB) available
  • First CAP® derived therapeutic proteins have passed human phase I clinical trials reflecting regulatory compliance of CAP® technology in clinical development

 

CAP-T® cell line for transient protein expression

  • Incorporates ALL advantages of parental CAP® cells
  • Proceed within two weeks from gene to milligram and gram amounts of protein
  • Efficient and scalable transfection using different commercial reagents